EcoR1 Capital Makes $4.7M Open Market Purchase of Atara Biotherapeutics Stock
ATRA has more than doubled off its 52-week low of $3.92.
Summary
EcoR1 Capital, a 10% owner, made a substantial open-market purchase of Atara Biotherapeutics shares, investing over $4.7 million, signaling strong conviction amidst recent company challenges.
Key Events · Ownership and Investor Activity · ATRA
-
Major Insider Purchase
EcoR1 Capital, a 10% owner, acquired 507,407 shares of Atara Biotherapeutics common stock for $4,744,255 at an average price of $9.35 per share.
-
Significant Stake
This purchase represents a substantial investment, increasing EcoR1 Capital's indirect holdings to 1,552,000 shares.
-
Timing Amidst Challenges
The transaction occurred on May 7, 2026, the same day Atara Biotherapeutics announced a productive Type A meeting with the FDA, providing a potential path forward for its product, despite recent delisting notices and a going concern warning.
Analysis · ATRA · Life Sciences
EcoR1 Capital, a significant 10% owner, made a substantial open-market purchase of Atara Biotherapeutics stock, investing over $4.7 million. This transaction, representing more than 6% of the company's market capitalization, is particularly notable given the severe challenges Atara Biotherapeutics has recently faced, including a Nasdaq delisting notice, a going concern warning, and prior FDA setbacks. The purchase occurred on the same day the company announced a productive Type A meeting with the FDA, establishing a potential path forward for its lead product. This large investment by a major institutional holder suggests strong conviction in the company's ability to navigate its current difficulties and capitalize on future opportunities.
At the time of this filing, ATRA was trading at $9.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $74.7M. The 52-week trading range was $3.92 to $19.15. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.